Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: Dr Pi-Sunyer and colleagues1 reported the results of the RIO-North America trial on the efficacy of rimonabant for weight loss. In this study, patients who received 20 mg of rimonabant daily had a 2.7-fold higher rate of psychiatric disorders (leading to early withdrawal or removal from the study) compared with those receiving placebo. Psychiatric adverse events have accounted for about half of all early terminations attributed to adverse events with the 20 mg of rimonabant dose in all RIO trials published to date. In the RIO-Europe trial,2 of the 14.5% of patients who withdrew early during treatment with 20 mg of rimonabant daily, 7.0% were attributed to psychiatric adverse events. In the RIO-Lipids trial,3 psychiatric adverse events accounted for 7.5% of patients withdrawing early during treatment with 20 mg of rimonabant daily, whereas only 2.3% withdrew in the placebo group for the same reasons (a 3.3-fold increase in risk with rimonabant).
Gadde KM. Effect of Rimonabant on Weight and Cardiometabolic Risk Factors. JAMA. 2006;296(6):649-651. doi:10.1001/jama.296.6.649